Core Viewpoint - Enovis Corporation will host an investor conference call and live webcast to discuss its fourth quarter and full year 2024 financial results on February 26, 2025 [1] Group 1: Conference Call/Webcast Information - Investors can access the live webcast via a link on the Enovis website, and those participating by phone can dial (833) 685-0901 for U.S. callers or (412) 317-5715 for international callers [2] - A replay of the call will be available on the Enovis website later that day [2] Group 2: About Enovis - Enovis Corporation is an innovation-driven medical technology growth company focused on developing clinically differentiated solutions for better patient outcomes [3] - The company offers a wide range of products, services, and integrated technologies aimed at enhancing active lifestyles in orthopedics and beyond [3] - Enovis is listed on the New York Stock Exchange under the symbol ENOV [3] Group 3: Availability of Information - Enovis routinely announces material information through SEC filings, press releases, public conference calls, webcasts, and its Investor Relations website [4] - The company encourages stakeholders to review the information shared on its Investor Relations website for potentially material updates [4]

Industry Overview - The Medical Info Systems industry is rapidly expanding, driven by advancements in healthcare resource management and the adoption of digital healthcare and telemedicine, particularly influenced by the latest GenAI wave [1][2] - The industry comprises companies that develop and market healthcare information systems, providing software and hardware solutions for secure access to real-time clinical, administrative, and financial data [5] Market Trends - The use of AI in the medical device market is projected to grow at a CAGR of 29.9% from 2026 to 2029, driven by a patient-centric approach, increased healthcare expenditure, and regulatory support [3] - The global AI in healthcare market is expected to reach $95.65 billion by 2025, enhancing diagnostics and patient monitoring through AI-powered tools [9] - The global smart healthcare products market was valued at $145.9 billion in 2023 and is projected to reach $485.71 billion by 2032, with a CAGR of 12.78% [12] Key Companies - Enovis is a medical technology company focused on reconstructive surgery, rehabilitation, and pain management, with a projected earnings growth of 16.3% for 2024 and 14.3% for 2025 [19][20] - Omnicell develops automation solutions for medication management, targeting revenues of $1.9 billion to $2 billion by 2025, representing a CAGR of 14%-15% from 2021 to 2025 [21] - Phreesia provides an integrated SaaS-based software and payment platform, enabling approximately 150 million patient visits in 2023, with a projected earnings growth of 56.2% for 2024 [22][23] Industry Performance - The Zacks Medical Info Systems industry has underperformed the S&P 500 and the broader medical sector over the past year, with a decline of 6.6% compared to the sector's decline of 4.4% [17] - The industry is currently trading at a forward 12-month price-to-sales ratio of 5.63X, compared to the S&P 500's 5.51X and the sector's 2.86X [18]

Core Insights - The Medical Info Systems industry is rapidly expanding, driven by advancements in AI and telemedicine, with significant growth expected by 2025 due to new federal policies and projects like Trump's $500 billion Stargate initiative [1][4]. Industry Overview - The Zacks Medical Info Systems industry includes companies that develop healthcare information systems, providing software and hardware solutions for real-time access to clinical, administrative, and financial data [3]. - Key players like Omnicell and Allscripts are generating substantial revenue from software sales, IT outsourcing, and maintenance contracts [3]. Market Trends - The medical device market is projected to grow at a CAGR of 29.9% from 2026 to 2029, driven by a patient-centric approach and increasing healthcare expenditure [2]. - The global AI in healthcare market is expected to reach $95.65 billion by 2025, enhancing diagnostics and patient monitoring through AI-powered tools [4]. - The smart healthcare products market was valued at $145.9 billion in 2023 and is anticipated to grow to $485.71 billion by 2032, at a CAGR of 12.78% [5]. Cybersecurity Concerns - The increasing interconnectivity of healthcare systems has raised cybersecurity risks, with notable incidents affecting companies like Henry Schein and Change Healthcare [6]. Industry Performance - The Zacks Medical Info Systems industry has underperformed the S&P 500 and the broader medical sector over the past year, with a decline of 6.6% compared to the sector's 4.4% drop [9]. Valuation Metrics - The industry is currently trading at a forward price-to-sales ratio of 5.63X, compared to the S&P 500's 5.51X and the sector's 2.86X [11]. Company Highlights - **Enovis**: A medical technology company with a Zacks Rank 2 (Buy), expected to see a 16.3% earnings improvement in 2024 and 14.3% growth in 2025 [14][15]. - **Omnicell**: Also holding a Zacks Rank 2, targeting revenues of $1.9 billion to $2 billion by 2025, with a CAGR of 14%-15% from 2021 to 2025 [17][18]. - **Phreesia**: Provides a SaaS-based platform, enabling approximately 150 million patient visits in 2023, with a Zacks Rank 2 and a projected 56.2% earnings improvement in 2024 [20][21].

Wilmington, DE, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Enovis™, a global medical technology innovator headquartered in the United States, announced recently that Davide Visentin will succeed Dr. Benjamin Reinmann as President of Enovis International Surgical, effective March 1, 2025. Visentin is a successful MedTech executive who comes to Enovis with more than 20 years of healthcare experience. Most recently, he was the Vice President and General Manager of the Integrated Diagnostic Solutions Business Unit for B ...

Group 1 - Maplebear Inc. will replace Enovis Corp. in the S&P MidCap 400 effective January 14, 2025 [1] - Enovis Corp. will replace Arch Resources Inc. in the S&P SmallCap 600 on the same date [1] - CONSOL Energy Inc. is acquiring Arch Resources, and following the merger, it will be renamed Core Natural Resources Inc. with a new ticker CNR [1] Group 2 - The changes in the S&P indices include the addition of Maplebear to the S&P MidCap 400 and the deletion of Enovis from the same index [2] - Enovis will be added to the S&P SmallCap 600 while Arch Resources will be removed from that index [2]

Core Viewpoint - Enovis Corporation is set to present at the 43rd Annual J.P. Morgan Healthcare Conference, highlighting its commitment to innovation in medical technology [1] Company Overview - Enovis Corporation is an innovation-driven medical technology growth company focused on developing clinically differentiated solutions that improve patient outcomes and transform workflows [2] - The company offers a wide range of products, services, and integrated technologies aimed at supporting active lifestyles, particularly in orthopedics [2] - Enovis's shares are traded on the New York Stock Exchange under the symbol ENOV [2]

Group 1 - The article highlights the focus on buy-write or covered call opportunities in selected biotech stocks, indicating a trend among investors in the biotech sector [1] - Enovis Corporation (NYSE: ENOV) is spotlighted for its solid third-quarter performance, strong analyst support, and reasonable stock valuation [2] - The Biotech Forum offers a model portfolio featuring 12-20 high upside biotech stocks, along with live chat discussions and weekly market commentary [2]

Enovis (ENOV) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.Individual investo ...

Shares of Enovis (ENOV) have gained 23.6% over the past four weeks to close the last trading session at $47.86, but there could still be a solid upside left in the stock if short-term price targets of Wall Street analysts are any indication. Going by the price targets, the mean estimate of $66.50 indicates a potential upside of 39%.The average comprises 10 short-term price targets ranging from a low of $50 to a high of $75, with a standard deviation of $8.58. While the lowest estimate indicates an increase ...

Enovis Corporation (NYSE:ENOV) Q3 2024 Results Conference Call November 6, 2024 8:30 AM ET Company Participants Kyle Rose - Vice President of Investor Relations Matt Trerotola - CEO & Chairman Ben Berry - Senior VP & CFO Conference Call Participants Vic Chopra - Wells Fargo Vijay Kumar - Evercore ISI Robbie Marcus - JPMorgan Xuyang Li - Jefferies Jeff Johnson - Baird Brandon Vazquez - William Blair Caitlin Cronin - Canaccord Danielle Antalffy - UBS Mike Matson - Needham & Company Operator Good day, and wel ...